Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...
Travere Therapeutics, Inc. ( TVTX) Q4 2025 Earnings Call February 19, 2026 4:30 PM EST Good afternoon, and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2025 Financial Results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results